RxDoctor Payments DataLook up a doctor →

Glen Tonnessen, MD

Cardiovascular Disease · Flemington, NJNPI 1154387389

Payments from drug & device makers

$90,372in general payments, 2019–2025

Across 422 payments — averaging $214.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$66K
  • Angiodynamics, Inc.$17K
  • Johnson & Johnson$965
  • Novartis$838
  • Amgen$781
  • Boston Scientific$690
  • plus $4K from 32 others

What the payments were for

  • Consulting fees$2,0008%
  • Food & beverage$7,45930%
  • Education$15,00061%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,372 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$527,684
Medicare patients
541
Services billed
2,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban111$121,112
Repatha SureclickEvolocumab48$54,505
XareltoRivaroxaban40$51,024
EntrestoSacubitril/Valsartan17$22,939
Ezetimibe176$4,209
Rosuvastatin Calcium255$4,108
Metoprolol Succinate177$2,862
Atorvastatin Calcium189$2,162
Ranolazine ErRanolazine13$1,663
Losartan Potassium126$1,450
Carvedilol100$1,281
Nebivolol Hcl23$1,244
FenofibrateFenofibrate Nanocrystallized24$1,042
Amlodipine Besylate128$997
Potassium Chloride20$983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$500$121,112111 claims
Johnson & JohnsonXarelto$965$51,02440 claims
NovartisEntresto$838$22,93917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Flemington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →